Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analysts give Hims & Hers an average consensus rating of “Hold” from 18 brokers (1 sell, 13 hold, 4 buy) with a 12‑month average price target of about $32.53.
• Company insiders have been net sellers recently — including the COO’s sale of 97,289 shares — with insiders offloaded 204,857 shares (~$5.29M) in the past 90 days while still owning 13.71% of the stock.
• Hims & Hers is expanding digital offerings (including access to Novo Nordisk GLP‑1 treatments and planned Canada/Europe rollouts) which may diversify revenue, but faces competitive pressure from entrants like Amazon into weight‑management services.

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) have been assigned an average recommendation of "Hold" from the eighteen brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $32.5333.

Several analysts have recently issued reports on the company. Truist Financial reiterated a "hold" rating and set a $18.00 price target (down from $37.00) on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Citigroup upgraded Hims & Hers Health from a "sell" rating to a "neutral" rating and upped their price target for the stock from $13.25 to $24.00 in a research note on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $25.00 to $28.00 and gave the stock a "hold" rating in a research note on Tuesday, March 10th. Bank of America upped their price target on Hims & Hers Health from $30.00 to $32.00 and gave the stock a "neutral" rating in a research note on Friday, April 24th. Finally, Zacks Research upgraded Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research note on Wednesday, February 25th.

Insider Buying and Selling

In related news, insider Irene Becklund sold 5,529 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $136,511.01. Following the completion of the sale, the insider owned 8,752 shares in the company, valued at $216,086.88. This represents a 38.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Michael Chi sold 97,289 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $2,402,065.41. Following the sale, the chief operating officer owned 407,282 shares of the company's stock, valued at approximately $10,055,792.58. The trade was a 19.28% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 204,857 shares of company stock worth $5,285,706. Insiders own 13.71% of the company's stock.

Institutional Trading of Hims & Hers Health

Hedge funds have recently added to or reduced their stakes in the business. Quent Capital LLC bought a new stake in Hims & Hers Health during the 3rd quarter valued at approximately $28,000. Flagship Harbor Advisors LLC bought a new stake in Hims & Hers Health during the 4th quarter valued at approximately $28,000. Binnacle Investments Inc bought a new stake in Hims & Hers Health during the 3rd quarter valued at approximately $28,000. Bogart Wealth LLC boosted its stake in Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company's stock valued at $29,000 after purchasing an additional 632 shares during the period. Finally, Geneos Wealth Management Inc. bought a new stake in Hims & Hers Health during the 1st quarter valued at approximately $30,000. Institutional investors own 63.52% of the company's stock.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $26.31 on Thursday. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. Hims & Hers Health has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The stock's 50-day moving average is $21.68 and its two-hundred day moving average is $30.76. The firm has a market cap of $6.00 billion, a P/E ratio of 51.60, a PEG ratio of 2.78 and a beta of 2.32.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.06. The company had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The firm's revenue was up 28.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.11 EPS. Analysts predict that Hims & Hers Health will post 0.61 earnings per share for the current fiscal year.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Company expands its digital-first care offerings — announced access to Novo Nordisk GLP-1 treatments, new cancer-detection and Labs tools, and planned rollouts into Canada and Europe, which could boost revenue diversification and addressable market. Hims & Hers Expands Digital-First Access to Personalized Healthcare
• Positive Sentiment: Board nomination of Kofi Amoo‑Gottfried signals stronger marketing focus — adding a seasoned CMO-level marketer (DoorDash/Meta experience) suggests management is prioritizing customer acquisition and retention metrics, which could improve growth efficiency. Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors
• Positive Sentiment: Analyst/momentum recognition could attract flows — Zacks and other outlets flagged HIMS as a top-ranked momentum stock, which can drive short-term buying from momentum-focused funds and retail investors. Hims & Hers Health, Inc. (HIMS) is a Top-Ranked Momentum Stock: Should You Buy?
• Neutral Sentiment: Value/peer comparisons land mixed — write-ups comparing HIMS to Omnicell and other peers highlight differing valuation cases; useful for longer‑term investors but less likely to move the stock near-term. OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?
• Negative Sentiment: Competitive pressure from Amazon/One Medical into weight‑management is weighing on momentum — media coverage flagged Amazon’s entry as a threat to HIMS’ addressable market for GLP‑1/weight solutions, prompting selling pressure despite HIMS’ product moves. Why Hims & Hers Health (HIMS) Shares Are Trading Lower Today

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.